Early-stage LOXO-292 data sends Loxo shares soaring

18 May 2018

Shares of US biotech Loxo Oncology (Nasdaq: LOXO) leapt 21% to $167.53 after the firm released an abstract of early-stage data for its RET inhibitor LOXO-292, which is due to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting next month.

According to the abstract, these Phase I results demonstrated that as of a January 5, 2018, cut-off date, in 32 evaluable patients administered LOXO-292, overall response rates of 65% and 83% were seen in non-small-cell lung cancer (NSCLC) and papillary thyroid cancer, respectively. Meanwhile, in 14 evaluable patients with medullary thyroid cancer (MTC), 79% experienced tumour shrinkage ranging from 9% to 45%.

The final ASCO results will cover data through April.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK